Evaxion Unveils Promising Preclinical Data for AML Vaccine EVX-04 at ASH Meeting
Reuters
Dec 07, 2025
Evaxion Unveils Promising Preclinical Data for AML Vaccine EVX-04 at ASH Meeting
Evaxion A/S, a clinical-stage biotechnology company specializing in AI-powered immunology, has announced new preclinical data for its acute myeloid leukemia (AML) vaccine candidate, EVX-04. The results, which demonstrate that EVX-04 triggers strong specific T-cell responses and effectively prevents tumor growth in preclinical models, were presented at the American Society of Hematology $(ASH)$ Annual Meeting and Exposition in Orlando, Florida. EVX-04 is an off-the-shelf therapeutic cancer vaccine developed using Evaxion's proprietary AI-Immunology™ platform and targets non-conventional endogenous retrovirus (ERV) tumor antigens. The company indicates that the off-the-shelf vaccine concept underlying EVX-04 has potential applications across other hard-to-treat cancers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143197-en) on December 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.